You are here:

golimumab (Simponi)

Advice

following a full submission

golimumab (Simponi®) is not recommended for use within NHS Scotland.

Indication under review: treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.

In a study of adults with moderately to severely active ulcerative colitis who had inadequate response or intolerance to conventional therapy, a greater proportion of patients given golimumab induction therapy achieved a clinical response compared with placebo.  In patients who had a clinical response to golimumab induction, golimumab maintenance treatment was associated with a greater clinical response rate over 54 weeks, compared with placebo. 

The company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Drug Details

Drug Name: golimumab (Simponi)
SMC Drug ID: 946/13
Manufacturer: MSD
Indication: for the treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
BNF Category:
Sub Category: 1.5 Chronic bowel disorders
Submission Type: Full submission
Status: Superseded
Date Advice Published: 13 October 2014

Archived Advice

Non submission 13 January 2014

Back